MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 12-23-2023
Aerie Pharmaceuticals Total Liabilities 2011-2025 | AERI
Annual Total Liabilities Aerie Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 449 M | 378 M | 286 M | 57.2 M | 155 M | 143 M | 140 M | 133 M | 3.48 M | 6.24 M | 3.81 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 449 M | 3.48 M | 159 M |
Quarterly Total Liabilities Aerie Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 540 M | 526 M | 521 M | 449 M | 425 M | 395 M | 373 M | 378 M | 307 M | 295 M | 285 M | 286 M | 286 M | 286 M | 286 M | 57.2 M | 57.2 M | 57.2 M | 57.2 M | 155 M | 155 M | 155 M | 155 M | 143 M | 143 M | 143 M | 143 M | 140 M | 140 M | 140 M | 140 M | 132 M | 133 M | 133 M | 133 M | 3.48 M | 3.48 M | 3.48 M | 3.48 M | 6.24 M | 6.24 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 540 M | 3.48 M | 199 M |
Total Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
107 M | - | - | $ 142 M |  USA |
 |
Canopy Growth Corporation
CGC
|
430 M | $ 1.2 | 0.42 % | $ 129 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
10.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Cronos Group
CRON
|
218 M | $ 2.67 | 0.19 % | $ 1.39 B | Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.6 M | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
6.15 B | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
26.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
63.2 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
173 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
244 M | $ 4.32 | -3.79 % | $ 86.3 M | Canada |
 |
Endo International plc
ENDP
|
10.3 B | - | - | $ 28.9 M |  Irlanda |
 |
Zomedica Corp.
ZOM
|
13.2 M | - | -0.21 % | $ 98 M | USA |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
250 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
367 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.29 M | - | - | $ 55.5 M | USA |
 |
Emergent BioSolutions
EBS
|
1.17 B | $ 12.28 | -1.17 % | $ 629 M | USA |
 |
Athenex
ATNX
|
228 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
90.4 M | $ 21.57 | -0.12 % | $ 2.05 B |  France |
 |
Evolus
EOLS
|
227 M | $ 6.67 | -3.33 % | $ 414 M | USA |
 |
Harrow Health
HROW
|
242 M | $ 50.64 | 1.09 % | $ 1.65 B | USA |
 |
China Pharma Holdings
CPHI
|
7.14 M | $ 1.27 | -1.17 % | $ 22.2 M |  China |
 |
OrganiGram Holdings
OGI
|
102 M | $ 1.71 | -4.47 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
113 M | $ 5.22 | -1.14 % | $ 687 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
36.5 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 7.15 | -0.69 % | $ 2.61 B | Canada |
 |
Lannett Company
LCI
|
735 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
9.28 M | $ 3.66 | 1.25 % | $ 4.54 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
53 M | $ 4.02 | -2.31 % | $ 56.5 M | USA |
 |
Rockwell Medical
RMTI
|
30.9 M | $ 0.82 | -5.16 % | $ 19.1 M | USA |
 |
Pacira BioSciences
PCRX
|
775 M | $ 26.19 | -1.21 % | $ 1.21 B | USA |
 |
Sundial Growers
SNDL
|
216 M | $ 1.73 | -0.29 % | $ 3.37 M | Canada |
 |
PetIQ
PETQ
|
478 M | - | 1.64 % | $ 400 M | USA |
 |
Veru
VERU
|
28.1 M | $ 2.2 | -8.33 % | $ 297 M | USA |
 |
Jupiter Wellness
JUPW
|
9.51 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
5.33 B | $ 13.87 | 0.4 % | $ 1.91 B | USA |
 |
ProPhase Labs
PRPH
|
24 M | $ 0.45 | -13.46 % | $ 7.13 M | USA |
 |
cbdMD
YCBD
|
8.62 M | $ 1.46 | -14.41 % | $ 6.3 M | USA |
 |
Radius Health
RDUS
|
434 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
94.8 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
12.2 M | $ 4.41 | -2.22 % | $ 133 M | USA |
 |
OptiNose
OPTN
|
194 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
148 M | $ 9.56 | -3.82 % | $ 679 M | USA |
 |
PLx Pharma
PLXP
|
25 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
51.4 M | $ 5.7 | -2.48 % | $ 233 M | USA |
 |
SCYNEXIS
SCYX
|
55.4 M | $ 0.62 | 6.08 % | $ 29.7 M | USA |
 |
Tricida
TCDA
|
168 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
977 M | $ 9.33 | -2.81 % | $ 5.77 B | Canada |
 |
TherapeuticsMD
TXMD
|
14 M | $ 1.67 | -4.02 % | $ 17.4 M | USA |